Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension

NCT ID: NCT03424317

Last Updated: 2021-07-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate the therapeutic effect of sodium intake reduction by education in patients with resistant hypertension.

The study was designed to maximize the compliance to antihypertensive agents and use optimal doses of antihypertensive agents including diuretics for 2 months before randomization. Patients will be assigned randomly to receiving (1) education of sodium intake reduction and exercise, or (2) education of exercise alone. Education of sodium intake reduction will be blinded to patients, and education of exercise will be provided to both group to blind the subjects. Daytime ambulatory blood pressure is adopted for diagnosis of resistant hypertension to avoid white-coat effect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of 3 phases. The first phase is to exclude pseudo-resistant hypertension by improving compliance to antihypertensive medications. Patients should visit with a prescribed antihypertensive drugs to calculate compliance to medication. If patient has compliance to medication \>= 85% \[= (the number of pills dispensed - the number of pills counted) / the number of pills expected to have been taken (calculated by multiplying the daily dose by the number of days since the date dispensed)\], ambulatory blood pressure will be measured.

If the patient had compliance to medication \>= 85%, and daytime ambulatory blood pressure \>=135/85 mmHg, he will be entered into first phase of treatment. If patient had compliance to medication \<85%, patients will be asked to enhance medication adherence to 85% or more, and revisit after 1 months.

In the first phase of treatment, dose of current antihypertensive medications (diuretics should be included) will be escalated to optimal doses. Three or more classes of antihypertensive drugs should be prescribed, and educate to keep compliance to medication \>=85%. The duration of second phase of treatment is 2 months. After start of first phase, there is a monitoring visit monitoring of adverse drug reaction of diuretics for safety. If there is adverse drug reaction, the dose of suspected drug will be decreased. After 2 months of treatment, if daytime ambulatory blood pressure is \>= 135/85 mmHg with compliance to medication \>=85%, the patients will be entered into second phase of treatment.

In the second phase of treatment, patients will be randomly assigned to receive either education of exercise or education of exercise and low sodium diet (intensive education with education materials). To the patients assigned to exercise education, detailed training of diet control using educational materials will not be provided. The patients will be blinded to educational group assignments. The duration of second phase of treatment is 1 month. Before start and after completion of second phase of treatment, the amount of sodium intake will be measured by 24-hour urine sodium excretion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sodium Intake Resistant Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

single blind, randomized
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sodium intake reduction and exercise

education of sodium intake reduction and regular exercise

Group Type ACTIVE_COMPARATOR

Sodium intake reduction

Intervention Type BEHAVIORAL

Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively

Exercise

Intervention Type BEHAVIORAL

Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively

Exercise

education of regular exercise only

Group Type PLACEBO_COMPARATOR

Exercise

Intervention Type BEHAVIORAL

Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium intake reduction

Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively

Intervention Type BEHAVIORAL

Exercise

Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* individuals who agreed to participate in the study and submitted written informed consent
* individuals aged 20 or more years
* Hypertensive patients whose blood pressure is not controlled normally while taking three or more antihypertensive agents including diuretics
* Diuretics should be Hydrochlorothiazide or Indapamide

Exclusion Criteria

* Systolic blood pressure ≥ 220 mmHg
* Chronic kidney disease: estimated Glomerular filtration rate by Modification of Diet in Renal Disease formula ≤ 30 mL/min
* Hyperkalemia (\>5.5 mmol/L) or hypokalemia (\<3.5 mmol/L)
* Hyponatremia (\<135 mmol/L)
* Major cardiovascular events (MI, unstable angina, coronary revascularization, stroke) within 6 month of screening
* Retinal bleeding within 3 months
* Heart failure stage 3 or 4
* Severe liver disease
* Pregnancy or women in the fertile age not using efficient contraceptive methods
* Alcoholism
* Renovascular disease
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DongGuk University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Moo-Yong Rhee

Proffessor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moo-Yong Rhee, MD

Role: PRINCIPAL_INVESTIGATOR

Dongguk University Ilsan Hospital/Cardiovascular Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dongguk University Ilsan Hospital

Goyang-si, Gyeonggi-do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DUMC-C1701

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Activating Media for Salt Reduction
NCT03074851 COMPLETED NA